Bifogade filer
Prenumeration
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
SECOND QUARTER 2024 (APR – JUN)
Net sales amounted to SEK 212.5 (216.2) million, a decrease of 2 percent compared with the corresponding period in the preceding year.
License revenue amounted to SEK 67.1 (75.7) million and accounted for 32 (35) percent of net sales.
The gross margin was 68 (68) percent.
Operating profit amounted to SEK 33.4 (47.5) million.
Net profit amounted to SEK 28.6 (38.8) million, corresponding to earnings per share of SEK 0.56 (0.76).
Cash flow from operating activities amounted to SEK 30.0 (85.1) million. As of June 30, 2024, cash and cash equivalents amounted to SEK 667.1 million (574.4).
FIRST HALF OF 2024 (JAN – JUN)
Net sales amounted to SEK 400.7 (445.3) million, a decrease of 10 percent compared with the preceding year.
License revenue amounted to SEK 130.3 (146.3) million and accounted for 33 (33) percent of net sales.
The gross margin was 67 (69) percent.
Operating profit amounted to SEK 59.4 (100.8) million.
Net profit amounted to SEK 52.4 (88.6) million, corresponding to earnings per share of SEK 1.03 (1.74).
Cash flow from operating activities amounted to SEK 58.5 (145.6) million.
Gothenburg, Sweden, August 22, 2024
Surgical Science Sweden AB (publ)
This report, in its entirety, is available through the attachment or via:
https://surgicalscience.com/aktien/pressmeddelanden/
https://surgicalscience.com/aktien/finansiella-rapporter/
This is a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.